• Consensus Rating: Buy
  • Consensus Price Target: $11.50
  • Forecasted Upside: 671.81%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.49
▼ -0.08 (-5.10%)

This chart shows the closing price for APGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Apexigen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APGN

Analyst Price Target is $11.50
▲ +671.81% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Apexigen in the last 3 months. The average price target is $11.50, with a high forecast of $15.00 and a low forecast of $8.00. The average price target represents a 671.81% upside from the last price of $1.49.

This chart shows the closing price for APGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Apexigen.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/8/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2023Roth CapitalReiterated RatingBuy$15.00Low
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$8.00Low
12/12/2022Brookline Capital ManagementReiterated RatingBuyLow
10/17/2022Roth CapitalInitiated CoverageBuyLow
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.91 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/11/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/10/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/10/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/9/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/8/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/7/2023

Current Sentiment

  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Apexigen logo
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. The company was founded in 2010 and is based in San Carlos, California.
Read More

Today's Range

Now: $1.49
Low: $1.47
High: $1.61

50 Day Range

MA: $1.39
Low: $0.65
High: $2.28

52 Week Range

Now: $1.49
Low: $0.61
High: $31.35

Volume

80,420 shs

Average Volume

4,841,630 shs

Market Capitalization

$33.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.06

Frequently Asked Questions

What sell-side analysts currently cover shares of Apexigen?

The following sell-side analysts have issued reports on Apexigen in the last year: Brookline Capital Management, EF Hutton Acquisition Co. I, and Roth Capital.
View the latest analyst ratings for APGN.

What is the current price target for Apexigen?

2 Wall Street analysts have set twelve-month price targets for Apexigen in the last year. Their average twelve-month price target is $11.50, suggesting a possible upside of 671.8%. Roth Capital has the highest price target set, predicting APGN will reach $15.00 in the next twelve months. EF Hutton Acquisition Co. I has the lowest price target set, forecasting a price of $8.00 for Apexigen in the next year.
View the latest price targets for APGN.

What is the current consensus analyst rating for Apexigen?

Apexigen currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APGN will outperform the market and that investors should add to their positions of Apexigen.
View the latest ratings for APGN.

What other companies compete with Apexigen?

How do I contact Apexigen's investor relations team?

Apexigen's physical mailing address is 280 PARK AVENUE SUITE 43W, NEW YORK NY, 10017. The company's listed phone number is 650-931-6236. The official website for Apexigen is www.apexigen.com. Learn More about contacing Apexigen investor relations.